Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

This is a phase 1, open-label, dose-escalation, safety study evaluating up to 3 dose levels
of ANX007 administered as single IVT injections. Approximately 9 to 15 eligible participants
are enrolled into one cohort each. All participants receive ANX007 in an open-label manner.
The primary objective is to evaluate the safety and tolerability of a single intravitreal
(IVT) injection of ANX007 in participants with primary open-angle glaucoma. Secondary
objectives are to evaluate the serum pharmacokinetics (PK) and immunogenicity. An exploratory
objective will evaluate the pharmacodynamic (PD) effect of ANX007 on serum C1q activity.

Inclusion Criteria:

- Male or female age 18 years and older

- Diagnosis of primary open-angle glaucoma

- Intraocular pressure <21 mm Hg on a stable IOP treatment regimen

- Reliable visual field testing

Exclusion Criteria:

- BCVA worse than 20/80 in either eye

- Extensive glaucomatous visual-field damage

- History of intraocular inflammatory or infectious eye disease in study eye

- Ocular trauma in study eye within the preceding 6 months

- History of uncomplicated cataract surgery less than 6 mos prior

- Any abnormality preventing reliable Tonopen tonometry in study eye

- Active malignancy within past 5 yrs

- Previous tx with another humanized monoclonal antibody

- History of any autoimmune or neurologic disease

- Concurrent use of glucocorticoid medications

- Receiving monoamine oxidase inhibitor therapy